K
KINIKSA PHARMACEUTICALS LTD
NASDAQ: KNSA (Kiniksa Pharmaceuticals Interna)
Last update: 17 hours ago48.42
-0.81 (-1.65%)
| Previous Close | 49.23 |
| Open | 48.98 |
| Volume | 341,611 |
| Avg. Volume (3M) | 693,211 |
| Market Cap | 3,725,338,624 |
| Price / Earnings (TTM) | 53.21 |
| Price / Earnings (Forward) | 48.31 |
| Price / Sales | 5.67 |
| Price / Book | 6.74 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2026 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Kiniksa Pharmaceuticals Interna | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 2.0 |
| Insider Activity | 2.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.40 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 48.38 | - | 12,156 | 588,107 |
| COLE G BRADLEY | - | - | 0 | 0 |
| LEVY RICHARD S | - | - | 0 | 0 |
| MALLEY THOMAS | - | - | 0 | 0 |
| MCCAIN TRACEY L | - | - | 0 | 0 |
| PATEL SANJ K | 48.43 | - | 900,000 | 43,587,000 |
| POPOVITS KIMBERLY J | - | - | 0 | 0 |
| QUART BARRY D | - | - | 0 | 0 |
| Aggregate Net Quantity | 912,156 | |||
| Aggregate Net Value ($) | 44,175,107 | |||
| Aggregate Avg. Buy ($) | 48.41 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PATEL SANJ K | Officer | 01 Jun 2026 | Acquired (+) | 900,000 | 48.43 | 43,587,000 |
| BAKER BROS. ADVISORS LP | Director | 29 May 2026 | Acquired (+) | 12,156 | 48.38 | 588,107 |
| COLE G BRADLEY | Director | 29 May 2026 | Option execute | 2,799 | - | - |
| LEVY RICHARD S | Director | 29 May 2026 | Option execute | 2,799 | - | - |
| MALLEY THOMAS | Director | 29 May 2026 | Option execute | 2,799 | - | - |
| MCCAIN TRACEY L | Director | 29 May 2026 | Option execute | 2,799 | - | - |
| POPOVITS KIMBERLY J | Director | 29 May 2026 | Option execute | 2,799 | - | - |
| QUART BARRY D | Director | 29 May 2026 | Option execute | 2,799 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |